Specifica Announces Antibody Discovery PlatformTransfer Agreement with Servier and its Subsidiary Symphogen
Specifica Announces Antibody Discovery PlatformTransfer Agreement with Servier and its Subsidiary Symphogen SANTA FE, N.M. – 17th March 2023 – Specifica, a Q2 Solutions company focused on innovative in vitro antibody libraries…
FDM DigitalMarch 29, 2023